TY - JOUR T1 - Somatostatin Receptor–Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 507 LP - 513 DO - 10.2967/jnumed.120.249607 VL - 62 IS - 4 AU - Christian Mirian AU - Anne Katrine Duun-Henriksen AU - Andrea Maier AU - Maria Møller Pedersen AU - Lasse Rehné Jensen AU - Asma Bashir AU - Thomas Graillon AU - Maya Hrachova AU - Daniela Bota AU - Martjin van Essen AU - Petar Spanjol AU - Christian Kreis AU - Ian Law AU - Helle Broholm AU - Lars Poulsgaard AU - Kåre Fugleholm AU - Morten Ziebell AU - Tina Munch AU - Martin A. Walter AU - Tiit Mathiesen Y1 - 2021/04/01 UR - http://jnm.snmjournals.org/content/62/4/507.abstract N2 - Somatostatin receptor (SSTR)–targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas. Methods: We performed an individual patient data meta-analysis, including all published data on meningioma patients treated with SSTR-targeted PRRT. The main outcomes were toxicity, response to treatment, progression-free survival (PFS), and overall survival (OS). We applied the Kaplan–Meier method to estimate survival probabilities and report incidence rates per 100 person-years. We applied Cox proportional hazards models to determine the effect of covariates. Results: We screened 537 papers and identified 6 eligible cohort studies. We included a total of 111 patients who had treatment-refractory meningioma and received SSTR-targeted PRRT. Disease control was achieved in 63% of patients. The 6-mo PFS rates were 94%, 48%, and 0% for World Health Organization grades I, II, and III, respectively. The risk of disease progression decreased by 13% per 1,000-MBq increase in the total applied activity. The 1-y OS rates were 88%, 71%, and 52% for World Health Organization grades I, II, and III, respectively. The risk of death decreased by 17% per 1,000-MBq increase in the total applied activity. The main side effects comprised transient hematotoxicity, such as anemia in 22% of patients, leukopenia in 13%, lymphocytopenia in 24%, and thrombocytopenia in 17%. Conclusion: To our knowledge, this individual patient data meta-analysis represents the most comprehensive analysis of the benefits of and adverse events associated with SSTR-targeted PRRT for treatment-refractory meningioma. The treatment was well tolerated, achieved disease control in most cases, and showed promising results regarding PFS and OS. ER -